HC Wainwright & Co. analyst Robert Burns downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral.
D-Wave Quantum’s Fast Anneal To Boost Quantum Processing And Drive Customer Growth, Analysts Say
Needham analyst reiterates Buy rating and $2.5 price target for D-Wave Quantum. Q1 revenues of $2.5M, bookings up 54%. New fast anneal feature introduced.